Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 January 2022, 15:00 HKT/SGT
Share:
    

Source: Arcensus GmbH
Arcensus has appointed Prof. Dr. Arndt Rolfs as New CEO

Hoboken, NJ, Rostock & Berlin, Germany, Jan 12, 2022 - (ACN Newswire) - Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that our Founder, Prof. Dr. Arndt Rolfs, a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE, has been appointed as the Chief Executive Officer of Arcensus GmbH.

Prof. Dr. Arndt Rolfs

Prof. Rolfs has succeeded the role from Mr. Michael Schlenk and assumed the responsibilities of CEO on January 01, 2022. We are very grateful for the hard work and dedication of Mr. Schlenk for successfully performing the duties of CEO in 2021 and constructing the organization of Arcensus. We are reassured that Mr. Schlenk will continue supporting Arcensus as an active member of our supervisory board.

Mr Schlenk wished the new CEO every success: "I wish Arndt and the operational team all the best for 2022. There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the Supervisory Board."

Prof Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well. Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus' genomic data already has a diagnostic yield of about 80% in all genetically suspect patients.

Prof Rolfs said: "Our expertise in the high-quality interpretation of Whole Genome DNA Sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases."

About Arcensus

Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides a highest-standard, secure, trusted, and comprehensive medical service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology including artificial intelligence. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.

From our offices in New Jersey - United States, Rostock and Berlin - Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone. For more information, visit https://arcensus-diagnostics.com/

Important Notice and Disclaimer
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus' actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.

Media Contact:
Arcensus GmbH
Awais Bhatti
+49 1525 7692031
marketing@arcensus-diagnostics.com

The press release is issued through EmailWire.Com - a global newswire with press release distribution services.


Topic: Press release summary
Source: Arcensus GmbH

Sectors: BioTech, Healthcare & Pharm, MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Augmented Reality DApp Switches Networks from Ethereum to Polygon  
Jan 29, 2022 01:00 HKT/SGT
Pixis appoints Neel Pandya as the CEO for Europe Business, in Addition to APAC  
Jan 28, 2022 20:00 HKT/SGT
IgY antibody technology against SARS-CoV-2 unveiled  
Jan 28, 2022 18:08 HKT/SGT
Honda Releases Production, Sales and Export Results for December 2021  
Friday, January 28, 2022 5:20:00 PM
Pakistan's Silkbank Taps Silverlake Axis to Grow its Credit Card Footprint  
Jan 28, 2022 16:40 HKT/SGT
What You Need to Know about Tezos (XTZ) in 2022  
Jan 28, 2022 16:00 HKT/SGT
EuroEyes Acquires 100% Issued Shares in London Vision Clinic Partners Limited   
Jan 28, 2022 15:55 HKT/SGT
Mazda Production and Sales Results for December 2021 and for January through December 2021  
Friday, January 28, 2022 3:54:00 PM
Fujitsu Establishes AI Ethics and Governance Office to Ensure the Safe and Secure Deployment of AI and Leading-edge Technologies in Society  
Friday, January 28, 2022 2:40:00 PM
TrueFlip Named Best Crypto iGaming Platform 2021 by Europe Gaming Awards  
Jan 28, 2022 14:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: